Dosimetric analysis for the selection of radionuclides in bone pain palliation targeted therapy: A Monte Carlo simulation

Document Type: Original Article

Authors

Department of Physics, Faculty of Science, University of Guilan, Rasht, Iran

Abstract

Introduction:The use of beta emitters is one of the effective methods for palliation of bone metastasis. The risk of normal tissue toxicity should be evaluated in the bone pain palliation treatment.
Methods: In this study, the Monte Carlo simulation code MCNPX was used for simulation a bone phantom model consisted of bone marrow, bone and soft tissue. Specific absorbed fractions were calculated for monoenergetic electrons, photons and eight betaemitters: 32P, 89Sr, 90Y, 153Sm, 166Ho, 177Lu, 186Re and 188Re. Beta and gamma S-factor, absorbed dose and cumulative dose of mentioned radionuclides were obtained to the selection of radionuclides with optimal radiation characteristics.
Results: The results show 177Lu gives a higher local dose to source organ. 177Lu has fewer side effects on critical organ including bone marrow in comparison with other radionuclides such as 89Sr, 32P and 90Y. Cumulative dose versus time shows after a long time, long half-life radionuclides delivering a higher dose in comparison with the short-half radionuclides.

Conclusion: According to the results, low energy β-emitters177Lu, 153Sm and 186Re can be used for bone pain palliation especially in vertebra. Different combination of these radionuclides can be used to improving therapeutic effects for tumors with different size.

Keywords

Main Subjects


  1. Botelho RV, de Oliveira MF, Rotta JM. Quantification of vertebral involvement in metastatic spinal disease. Open Orthop J. 2013 Aug 19;7:286-91.
  2. Greco C, Pares O, Pimentel N, Moser E, Louro V, Morales X, Salas B, Fuks Z. Spinal metastases: From conventional fractionated radiotherapy to single-dose SBRT. Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):454-63.
  3. Sciubba DM1, Gokaslan ZL. Diagnosis and management of metastatic spine disease. Surg Oncol. 2006 Nov;15(3):141-51.
  4. Bagheri R, Afarideh H, Ghannadi-Maragheh M, Bahrami-Samani A, Shirvani-Arani S. Production of 223Ra from 226Ra in Tehran Research Reactor for treatment of bone metastasis. J Radioanal Nucl Chem. 2015;304(3):1185-1191.
  5. Kaneko TS, Sehgal V, Skinner HB, Al-Ghazi MS, Ramsinghani NS, Marquez Miranda M, Keyak JH. Radioactive bone cement for the treatment of spinal metastases: a dosimetric analysis of simulated clinical scenarios. Phys Med Biol. 2012 Jul 7;57(13):4387-401.
  6. Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007 Aug;28(8):623-30.
  7. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005 Jan;46 Suppl 1:38S-47S.
  8. Ayati N, Aryana K, Jalilian A, Hoseinnejad T, Samani AB, Ayati Z, Shariati F, Zakavi SR. Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis. Asia Ocean J Nucl Med Biol. 2013 Spring;1(1):27-31.
  9. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005 Jun;6(6):392-400.
  10. Lyra M, Lagopati N, Charalambatou P, Vamvakas I. Patient-specific dosimetry in radionuclide therapy. Radiat Prot Dosimetry. 2011 Sep;147(1-2):258-63.
  11. Hosain F, Spencer RP. Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background. Semin Nucl Med. 1992 Jan;22(1):11-6.
  12. Stigbrand T, Adams JG. Targeted radionuclide tumor therapy: Biological aspects. New York: Springer; 2008.
  13. Guerra Liberal FD, Tavares AA, Tavares JM. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods. Med Phys. 2014 Nov;41(11):114101.
  14. Sartor O. Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol. 2004;6 Suppl 10:S3-S12.
  15. Alavi M, Omidvari S, Mehdizadeh A, Jalilian AR, Bahrami-Samani A. Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid. World J Nucl Med. 2015 May-Aug;14(2):109-15.
  16. Johari Daha F, Shafiei M, Sheibani S, Tavakoli YH, Mazidi M, Mirfalah MH, Babaei MH. Production of 177Lu and formulation of ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone-seeking radiopharmaceutical Iran J Radiat Res. 2010;7(4):229-234.
  17. Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett. 2012 Oct 28;323(2):135-46.
  18. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004 Aug;45(8):1358-65.
  19. Ogawa K, Kawashima H, Shiba K, Washiyama K, Yoshimoto M, Kiyono Y, Ueda M, Mori H, Saji H. Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol. 2009 Feb;36(2):129-35.
  20. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena KA, LaFrance N, Pauwels SA. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010 Apr 1;28(10):1652-9.
  21. Ferreira S, Dormehl I, Botelho MF. Radiopharmaceuticals for bone metastasis therapy and beyond: a voyage from the past to the present and a look to the future. Cancer Biother Radiopharm. 2012 Nov;27(9):535-51.
  22. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992 Jul;33(7):1316-23.
  23. Serafini AN. Therapy of metastatic bone pain. J Nucl Med. 2001 Jun;42(6):895-906.
  24. Dolezal J, Vizda J, Odrazka K. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Urol Int. 2007;78(1):50-7.
  25. Holmes RA. [153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992 Jan;22(1):41-5.
  26. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. Revised ed. New York: The Society of Nuclear Medicine; 1999.
  27. Stabin MG, da Luz LC. Decay data for internal and external dose assessment. Health Phys. 2002 Oct;83(4):471-5.
  28. Hughes HG, Egdorf  HW, Gallmeier FC, Hendricks  JS, Little RC, McKinney GW, Prael RE, Roberts TL, Snow E, Waters LS. MCNPX User's Manual Version 2.4.0 Technical Report LA-CP-02-408. Los Alamos National Laboratory; 2002.
  29. Amako K, Guatelli S, Ivanchenko VN, Maire M, Mascialino B, Murakami K, Nieminen P, Pandola L, Parlati S, Pia MG, Piergentili M. Comparison of Geant4 electromagnetic physics models against the NIST reference data. IEEE T Nucl Sci. 2005;52(4):910–918.
  30. Amato E, Lizio D, Baldari S.Absorbed fractions for photons in ellipsoidal volumes. Phys Med Biol. 2009 Oct 21;54(20):N479-87.
  31. Strigari L, Sciuto R, D'Andrea M, Pasqualoni R, Benassi M, Maini CL. Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation. Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1031-8.
  32. International Commission on Radiation Units & Measurements. Photon, electron, proton and neutron interaction data for body tissues. ICRU Report 46; 1992.
  33. Cherry SR, Sorenson JA, Phelps ME. Physics in nuclear medicine. Philadelphia: Elsevier Saunders; 2012.
  34. Knoll  GF. Radiation detection and measurement. 4th ed. John Wiley and Sons;2010.
  35. Agarwal KK1, Singla S, Arora G, Bal C. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):79-88.
  36. Beiki D, Haddad P, Fallahi B, Keyvan A, Gholamrezanezhad A, Mirzaei H, Saghari M, Amouzegar-Hashemi F, Kazemian A, Fard-Esfahani A, Eftekhari M. Effectiveness and complications of 153Sm-EDTMP in palliative treatment of diffuse skeletal metastases. Iran J Nucl Med. 2013;21(1):26–32.
  37. Zolghadri S, Yousefnia H, Jalilian AR, Ghannadi-Maragheh M. Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation. Asia Ocean J Nucl Med Biol. 2015 Winter;3(1):35-42.
  38. Bouchet LG, Bolch WE, Goddu SM, Howell RW, Rao DV. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med. 2000 Apr;41(4):682-7.
  39. Rösch F, Herzog H, Plag C, Neumaier B, Braun U, Müller-Gärtner HW, Stöcklin G. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. Eur J Nucl Med. 1996 Aug;23(8):958-66.
  40. Tomblyn M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control. 2012 Apr;19(2):137-44.